About HD Biosciences
HD Biosciences is a Healthcare company based in Shanghai (China) founded in 2002, and was acquired by WuXi AppTec in January 2017. Preclinical CRO services in gene manipulation-based target validation are provided. Its focus areas include Biopharma Outsourcing, CRO and Drug Discovery. Its competitors include Viva Biotech and Qyuns Therapeutics; 1 of its 2 listed competitors has raised funding.
Company details
Preclinical CRO offers a proprietary gene manipulation-based target validation platform. The company has developed a technology platform for drug discovery including comprehensive service platforms in target validation, plate-based pharmacology, hit identification, lead discovery, assay development, SAR-focused MedChem, therapeutic antibody discovery, in vitro and in vivo pharmacology, biomarker services, natural product-based lead discovery and DMPK. Their proprietary Advanced Gene Manipulation technology for target validation offers gene manipulation solutions such as knock-down, knock-out, knock-in, and over-expression, in order to understand the functional impact and mechanism of action.
- Headquarters Shanghai, China
- Stage Acquired
- SectorsHealthcare
- Website hdbiosciences.com
- Social LinkedIn X
- Acquired by WuXi AppTec (Jan 2017)
- InvestorsWuXi AppTec
& 3 more
- Acquired byWuXi AppTec
(Jan 2017)
Funding Insights of HD Biosciences
- Total Rounds 1
- Investors Count 3
All 1 funding rounds of HD Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2008 | Series A | – | Morningside |
4 investors in total: 4 institutional.
Investors in HD Biosciences
HD Biosciences has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include WuXi AppTec, Morningside China and Lilly Asia Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is focused on healthcare by Pfizer's investment arm. | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | ||
VC and private equity investments are made in China-US companies. | morningside.com.cn | Shanghai, China | ||
| lillyasiaventures.com | ||||
Provider of CRO and CDMO services | 2000 | wuxiapptec.com | Shanghai, China |
Investor details for HD Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of HD Biosciences
3 dated milestones of HD Biosciences across 15 years, from founding to its latest funding, stage changes and deals.
- Founded HD Biosciences is founded.
- Funding First funding round.
- Exit Acquired by WuXi AppTec.
Competitors of HD Biosciences
HD Biosciences has 2 listed competitors in our database, 1 of them funded. They include Viva Biotech and Qyuns Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| vivabiotech.com | 2006 | Shanghai, China | Drug discovery and development research services are provided. | |||
| qyuns.net | 2015 | Taizhou, China | $66.35M | Drug development services are provided to the biopharma sector. |
Detailed competitors of HD Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of HD Biosciences
Websites that share an audience with HD Biosciences (hdbiosciences.com).
Websites whose visitors overlap most with HD Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
ddtjournal.com | ddtjournal.com | 100% | #6,858,410 | – | |
| bioalternatives.com | 86% | View details | |||
laseratlanta.com | laseratlanta.com | 53% | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hd Biosciences
Complete news archive for HD Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HD Biosciences
HD Biosciences was founded in 2002 and raised its 1st funding round 6 years after it was founded.
HD Biosciences is headquartered in Shanghai, China.
Preclinical CRO offers a proprietary gene manipulation-based target validation platform. The company has developed a technology platform for drug discovery including comprehensive service platforms in target validation, plate-based pharmacology, hit identification, lead discovery, assay development, SAR-focused MedChem, therapeutic antibody discovery, in vitro and in vivo pharmacology, biomarker services, natural product-based lead discovery and DMPK. Their proprietary Advanced Gene Manipulation technology for target validation offers gene manipulation solutions such as knock-down, knock-out, knock-in, and over-expression, in order to understand the functional impact and mechanism of action.
HD Biosciences's top competitors include Viva Biotech and Qyuns Therapeutics.
HD Biosciences has 4 investors. Key investors include WuXi AppTec, Morningside China, Lilly Asia Ventures, and Pfizer Venture Investments.
Yes. HD Biosciences was acquired by WuXi AppTec in January 2017.